Abstract
The global health community has targeted the elimination of neglected tropical diseases (NTDs) including soil-transmitted helminthiasis by 2030. The elimination strategy has not changed from that of control using regular mass drug administration (MDA) with albendazole, WASH and education. Already doubts have been expressed about this achievement, principally because drugs do not interrupt transmission. We report here the findings of a cohort study aimed to identify host modifiable and environmental factors associated with hookworm infection and reinfection in rural communities in Kintampo North Municipality, Ghana. Faecal samples of 564 consented participants were screened for intestinal parasites at baseline, 9 months and 24 months using the Kato-Katz method. At each time point, positive cases were treated with a single dose of albendazole (400 mg) and their samples were again screened 10-14 days post-treatment to record treatment failures. The hookworm prevalence at the three-time points was 16.7%, 9.22% and 5.3% respectively, whilst treatment failure rates were 17.25%, 29.03% and 40.9% respectively. The intensities of hookworm infection (in eggs per gram) at the time points were 138.3, 40.5 and 135, which showed a likely association with wet and dry seasons. We posit that the very low intensity of hookworm infections in humans during the dry season offers a window of opportunity for any intervention that could drastically reduce the community worm burden before the rainy season.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by NIH/NIAID awards to MDW (U19AI129916) and MC (R01AI132452). The funding agency did not play any role in the design and execution of the study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approvals from the Noguchi Memorial Institute for Medical Research Ethics Review Board (NIRB #100/16-17), the Kintampo Health Research Center Ethics Review Committee (# KHRCIEC 2017-20) and NIH/NIAID (DMID Protocol# 17-0061).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Emails: ALamptey{at}noguchi.ug.edu.gh, JSumboh{at}noguchi.ug.edu.gh, yashong{at}noguchi.ug.edu.gh, Osabutey{at}noguchi.ug.edu.gh, mwilson{at}noguchi.ug.edu.gh
Emails: IAlarbi{at}noguchi.ug.edu.gh, IOwusu{at}noguchi.ug.edu.gh, kkoram{at}noguchi.ug.edu.gh
Email: michael.cappello{at}yale.edu
Emails: kwakupoku.asante{at}kintampo-hrc.org, dennis.adu-gyasi{at}kintampo-hrc.org, dennis.konadu{at}kintampo-hrc.org
Data Availability
All data underlying the findings reported in the submitted manuscript is provided as part of the submitted article.
